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Since Anthony van Leeuwenhoek, first microscopic observations of 
the unseen microbiota and the more recent realization that little of 
the microbes in the biosphere are known, humans have developed 
a deep curiosity to fully understand the inner workings of the mi-
crobial realm. Our ability to characterize the complexity of microbial 
communities in their natural habitats has dramatically improved over 
the past decade thanks to advances in high-throughput methodolo-
gies. By eliminating the need to isolate and culture individual species, 
metagenomics approaches have removed many of the obstacles that 
hindered research in the ecology of mixed microbial consortia, pro-
viding valuable information about the di versity, composition, func-
tion, and metabolic capability of the community. 
Microbes are the unseen majority with the capability to colonize ev-
ery environment, including our bodies. The establishment and com-
position of a stable human microbiome is determined by the host 
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genetics, im munocompetence, and life-style choices. Our life-style 
choices determine our exposure to many external and internal en-
vironmental factors that permanently or temporarily can influence 
our microbiome composition. Figure 1 illustrates some of the life-
style-related factors that might influence the microbiota of the skin, 
mouth, and gut. It is not limited to what we carry, touch, breath, and 
eat. Other dispersal vectors include secretion, excretions, aerosols, air 
flow, animals, moving surfaces, water, beverages, food, contact, wind, 
tools, toiletry, and others. These influ ence the microbiome member-
ship, who are present, and they have the ability to participate in the 
microbiome dynamic within an environment. The establishment of a 
microbial community is dependent on many en vironmental factors, 
including pH, temperature, altitude, weather, soil type, nutrient avail-
ability, relative humidity, air quality, pollutants, mi crobial competitors, 
and others. In other words, we are superorganisms interconnected 
with other living forms on this Earth.
Fig. 1. Microbiome of modern humans is influenced by life-style choices. During ev-
eryday life, humans are exposed to many external and internal environmental fac-
tors that can influence the composition of their microbiome. The human microbi-
ome is here represented by the microbiota of the skin, mouth, and gut, and next to 
each body site a series of environmental modifiers. Some of these modifiers, such as 
general health, diet, medications, and stress, can affect the microbiota of more than 
one body site, but others, such as toothbrush and toothpaste, can directly modify 
the microbiota of only one body site.
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The exploration of the microbial worlds uncovered the extreme mi-
crobial diversity throughout the biosphere, from hydrothermal vents 
on the ocean floor to the intestinal tract of animals. In addition to 
metage nomics, other technologies including metatranscriptomics, 
metapro teomics, metabolomics, and metalipidomics can provide bet-
ter insights of the microbial ecosystems dynamics. Fundamental gaps 
in knowledge still exist. We will take few examples to discuss the 
promises of the upcoming discoveries. 
Microbiome During Development and Disease 
Since the 1980s, advances in sequencing technologies have uncov-
ered the immense diversity and functional capabilities of the microbial 
world. More recently, the introduction of next-generation sequencing 
(NGS) combined with metagenomics approaches has allowed a better 
under standing of the complexity of the interactions between animals 
and their associated microbiota, in particular, the gut microbiome. 
The digestive tract of animals has coevolved with a diverse and 
com plex microbial community that responds to host diet and pro-
vides meta bolic signals to the host during its developmental stages 
among many other functions.1 The permeability of the gut facilitates 
the transport of metabolites produced by the microbiota, which allows 
the signaling and interactions between the gut microbiota and the 
host organs and tissues.2 Host immune and nervous system as well as 
behavior including mating can be influenced.1,3,4 The use of metage-
nomics approaches to understand the complex metabolic interactions 
between the human host and its microbiome has revealed extensive 
variability in the diversity and composition of the mi crobiome between 
individuals and throughout the life-span of the host. A representation 
of this knowledge is summarized in Figure 2. Our growing knowledge 
of the magnitude and complexity of the interac tions between the host 
and the gut microbiome is drastically changing our views of human 
health, disease, and aging.2 The lifelong changes in the complexity of 
the host–microbiome metabolic interactions offer the opportunity for 
the development of specific therapeutic interventions targeting the 
gut microbiome throughout the life-span of the host.
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Fig. 2. Gut microbiota in development and disease. The influence of the gut mi-
crobiota on human health is continuous from birth to old age. The maternal mi-
crobiota may influence both the intrauterine environment and the postnatal health 
of the fetus. At birth, about 100 microbial species populate the colon. Early envi-
ronmental factors (e.g., method of delivery), nutritional factors (e.g., breastfeeding 
or bottle feeding), and epigenetic factors have been implicated in the develop-
ment of a healthy gut and its microbial symbionts. Changes in gut microbial com-
position in early life can influence risk for developing disease later in life. During 
suckling, the microbial community develops rapidly; shifts in microbial diversity 
occur throughout childhood and adult life, and in old age, there is a decrease in 
the Bacteroidetes and an increase in the Firmicutes species. The gut microbiota is 
important for maintaining normal physiology and energy production throughout 
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Therapeutic Potential of Microbiota Modifications 
Metagenomic studies have uncovered the connections between 
the dis ease and the changes in the homeostasis of host–microbiota 
interac tions.2 Such findings have renewed the interest of the medical 
community toward therapeutic interventions targeting the gut mi-
crobiota. Although unknowingly, humans have performed microbial 
modification for hun dreds of years, the first deliberate use of micro-
bial modification for human health date from the beginning of the 
last century.5,6 In 1907, Ellie Metchnioff suggested that the consump-
tion of lactic acid bacteria could improve health and longevity, and 
initiated the modern probiotics movement. Probiotics are “live mi-
croorganisms that, when administered in adequate amounts, confer 
a health benefit on the host.”5,6 Although the application of compara-
tive genomics approaches have contributed to elucidate the genetic 
components that confer probiotic properties to certain taxa, metage-
nomics methodology allows more comprehensive studies of the effect 
of probiotics.5,7 Metagenomics together with other omics approaches 
can potentially identify the metabolites and metabolic pathways in-
ducing the host–microbiota feedback mechanism by which probiot-
ics can modulate health. 
Extensive multi-omics studies are needed to fully understand how 
changes in the ecology of the gut microbiota relate to disease and 
how to better design and utilize microbial modification therapies.8 
Which are the microbiome structural and homeostatic changes as-
sociated with the development of secondary infections following the 
life. Body temperature regulation, reproduction, and tissue growth are energy-
dependent processes that may rely in part on gut microbial energy production. 
Extrinsic environmental factors (such as antibiotic use, diet, stress, disease, and 
injury) and the mammalian host genome continually influence the diversity and 
function of the gut microbiota with implications for human health. Disruption of 
the gut microbiota (dysbiosis) can lead to a variety of different diseases, includ-
ing (A) inflammatory bowel disease, colon cancer, and irritable bowel syndrome; 
(B) gastric ulcers, nonalcoholic fatty liver disease, and obesity and metabolic syn-
dromes; (C) asthma, atopy, and hypertension; and (D) mood and behavior through 
hormone signaling. The gut microbiota is also important for drug metabolism and 
preventing the establishment of pathogenic microbes. (Reprinted with permission 
from the American Association for the Advancement of Science.2)
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administration of broad-spectrum antimicrobials?9 How are the ho-
meostasis and ecologi cal dynamics of the host-microbiome interac-
tions affected by the elimi nation of specific taxa after immunization? 
Microbiota modification will soon fall into the realm of personalized 
and preventive medicine.10–13 
So far, the best evidence of the therapeutic potential of microbiota 
modifications is fecal microbiota transplantation (FMT). The replace-
ment of the patient’s gut microbiome with the microbiome from a 
healthy donor has been very successful in the treatment of antibi-
otic-resistant Clostridium difficile infections. More in-depth metage-
nomics studies from patients with C. difficile infections before and 
after fecal trans plants are needed to determine if it is possible to ob-
tain the same therapeutic benefits by introducing selected members 
of the microbial community or if indeed the full replacement of the 
gut microbiome is needed.14,15 The efficacy of therapeutic interven-
tions based on micro biota modulation will have to be demonstrated 
by their ability to consis tently restore a healthy steady state. The suc-
cess of the first randomized clinical trial demonstrating the effective-
ness of the FMT for the treat ment of recurrent C. difficile infections 
has catalyzed the formation of FMT-patient advocacy groups, and the 
establishment of stools banks to ultimately encourage the develop-
ment of targeted therapies.14,16,17 The success of FMT suggests that it 
might be appropriate to establish strict regulations for the screening 
of infectious disease in microbiome trans plants, similar to the ones in 
place for organ transplants.14,16,17 
Challenges Ahead: Human Microbiome Information in the 
Health Care System 
In November 2013, the US Food and Drug Administration (FDA) ap-
proved the marketing of the NGS systems as diagnostic devices for 
human genome sequencing.18,19 The authorization by the FDA of the 
Illumina sequencing platform for whole human genome surveys in the 
clinical setting paves the way for the development of new sequenc-
ing-based clinical tests, potentially including microbiome profiling. It 
is pre dicted that in the future, the patient genome and microbiome 
data can be integrated allowing the identification of medically rele-
vant variants that might transform clinical research and patient care. 
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Potentially, these combined data sets can help inform about disease 
predisposition or re sponses to drugs allowing the design of person-
alized care and/or early therapeutic interventions. Many challenges 
need to be conquered before microbiome information is routinely in-
corporated in health care. 
Extensive studies of microbiome profile variations among healthy 
in dividuals are needed before microbiome data can be used for pre-
dicting disease predisposition, onset, and progression, and drug–re-
sponse mod ulation. Similar to the human genome sequencing, the 
full integration of microbiome data in the clinical setting requires ma-
jor research efforts in the collection of rigorous evidence supporting 
the role of the microbiome in health and disease, the development of 
appropriate regulatory and validation policies, the implementation of 
policies addressing patients’ rights, and the training of the physician 
and health care professionals in microbiome data interpretation.20 A 
lot of research and validation will be required before the approval by 
the FDA of microbiome pro filing in the clinical setting. Accuracy, preci-
sion, analytical sensitivity and specificity, reference range, and report-
able range will be scrutinized. In the United States, the Clinical Lab-
oratory Improvement Amendments (CLIA), which perform testing of 
clinical laboratories to ensure their accuracy in testing human sam-
ples, will have to develop new standards that can capture the micro-
biome complexity. As many other technologi cal advances and discov-
eries, there is likely to be a lapse of time before the actual adoption 
of the new technology into the clinical setting. 
Ethical Considerations of Microbiome Research 
In the 21st century, the Internet and other digital technologies have 
facilitated the access to personal information raising concerns re-
lated to privacy and data rights issues. The ease of the data accessi-
bility has serious implications for the regulation of research in human 
subjects. In microbiome research, those regulatory issues are related 
to the selection and recruitment of human subjects, the possibility of 
individual or group stigma associated with the research findings, pri-
vacy and confidentiality, and informational risks associated with dis-
closure of some of the find ings.21–25 Additionally, microbiome research 
subjects may be identified by the disclosure of information collected 
Rivera  &  I zard  in  Metagenomics  for  Microb iology  (2015 )       8
from the behaviors survey and/or from the microbiota samples. In ad-
dition to the issues related to research-generated data, unique to the 
human microbiome are issues re lated to informed consent for future 
use of stored microbiota samples.26–28 “Who owns your poop?” is the 
humorous and thought-provoking ques tion posed by Alice Hawkins 
and Kieran O’Doherty, while discussing the impact on microbiome re-
search of issues related to privacy, consent, ownership, return of re-
sults, governance, and benefit sharing.28 Although some ethical issues 
are unique to microbiome research, similar ethical concerns were ex-
tensively debated during the Human Genome Project and, more re-
cently, genome-wide association studies.24,29 
To better address the ethical issues facing contemporary research 
such as microbiome research, in 2011, the US Department of Health 
and Human Services issued an Advance Notice of Proposed Rulemak-
ing (ANPRM), entitled “Human Subjects Research Protections: Enhanc-
ing Protections for Research Subjects and Reducing Burden, Delay, 
and Ambiguity for Investigators,” proposing changes to the “Com-
mon Rule,” as the current federal policy for the Protection of Human 
Subjects is known.43 Some of the ANPRM proposed changes include: 
(1) adjusting Institutional Review Board (IRB) review to contemporary 
research, (2) establishing a single IRB review for multi-institution re-
search, (3) specific written con sent for the use of biospecimens, (4) 
standards for data security and pro tection of identifiable or potentially 
identifiable data, (5) implementing a systematic approach to the col-
lection and analysis of data on unantici pated problems and adverse 
events, and (6) extending the federal rules to apply to all research, re-
gardless of funding source, that is conducted at US institutions that 
receive some funding from a Common Rule agency for research using 
human subjects. The proposed revisions to the Common Rule present 
many challenges to the regulation of research using human subjects 
deserving immediate attention by the research community.30 
The ethical issues facing microbiome research require the 
implemen tation of novel guidelines on the proper and ethical collec-
tion and use of the data generated by this technology. At the same 
time, to stimulate and facilitate the process of discovery and to keep 
pace with the latest technological advances, it is imperative for the 
regulatory agencies to implement a more agile and adaptable eval-
uation system. 
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The artist, like the scientist, can expose and highlight the ethical 
and privacy issues associated with new technologies. To raise aware-
ness of our increasing access to biotechnologies, Gabriel Barcia-Co-
lombo created the art installation ‘DNA vending machine’.31 The instal-
lation shows visuals of individuals whom donated mouthwash from 
which DNA was extracted, as well as a packaged vial of that DNA. The 
instal lation is both troubling and natural. Both oral microbiome and 
human DNA should be present in the beautifully condensed genetic 
informa tion presented by the artist. One can just wonder how such 
material can be used, and if we should expect prepackaged microbi-
omes to be on the supermarket shelves. 
Another side of this ethics debate is whether the microbiota has 
rights. Under the assumption “for the benefit of all,” we have the tech-
nological capacity to permanently eradiate members of the microbi-
ota or, through synthetic biology, “create new microbiota.”32–34
Citizen Scientist, Crowdsourced Research, and the Microbiome 
The increasing evidence suggesting the important role played by the 
microbiota in development, aging, and many human diseases has spur 
great interest from the general public and has introduced the micro-
biome field to the citizen science movement.35–37 Using the citizen sci-
ence principles of crowdsourcing and crowdfunding, companies and 
open-sourced projects have been established to collect microbiome 
samples from donors and provide them with a snapshot of their own 
microbiome profile in exchange for a monetary contribution.33 Some 
large projects include the American Gut in association with the Hu man 
Food Project and several universities, the Home Microbiome study with 
the Alfred P. Sloan Foundation and Argonne National Laboratories, and 
the Project MERCCURI to analyze the space sta tion microbiome. On-
line resources, such as SciStarter and microBEnet, allow the identifi-
cation of active studies where individuals can be in volved. The popu-
larity and success of these types of projects is attrib uted to the need 
of the general public to access scientific information that can poten-
tially impact their lives and health. This need of infor mation is strongly 
felt in the case of the gut microbiome, as changes in the gut microbi-
ota have been associated with several debilitating human conditions. 
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The citizen science movement can empower the individuals but 
at the same time raises several ethical issues and imposes additional 
responsi bilities and concerns to the researchers involved in such proj-
ects.35,38–41 The research community needs to be aware of the implicit 
expectations of the citizen scientists and making sure that data col-
lection is not the only goal of the project. While moderating the high 
expectations of the citizen scientist, the researchers need to ensure 
the proper use of the collected data to help improve the health and 
knowledge of, for example, the human subjects.42 Properly used and 
integrated with other health status data, the generated microbiome 
profiles can potentially provide information very useful to both the hu-
man subjects and the research community. If rigorous studies corrob-
orate the observed associations between disease state and changes 
in microbiome structure, the infor mation could improve preventive 
health care and lead to earlier medical interventions.
Although of immense benefit to the research community and to the 
participants, the modality of data collection by citizen scientist pres-
ents serious concerns with privacy and security of the data. Microbi-
ome sam ples contain not only the individuals’ microbiome but also 
the genetic in formation that could potentially identify the sample do-
nor. A successful microbiome citizen science project requires the im-
plementation of the best practices for collection, management, se-
curity, analysis, and com munication of all the data collected.21–24 It is 
important to point out the well-known fact that research conducted 
using data collected from self-selected participants have method-
ological limitations. Because of selection bias, information bias, and 
confounding effects, the findings of research using self-selected par-
ticipants requires cautious interpretation.40 It requires the implemen-
tation of the proper analytical methodology to identify and possibly 
compensate for those biases and confounding eff ects.40 This type of 
collection efforts require the full awareness of the participants that 
the observed correlation or associations might lack ac curacy or gen-
erality because of those methodological limitations. 
The use of self-selected participants can potentially restrict the 
health benefits of microbiome profiling to a small sector of the popu-
lation, be cause the data collected is skewed based on socioeconomics, 
ethnicity, and/or disease state of the donor. Given the current fund-
ing situation, it can also limit the testing of alternate hypotheses.35–41 
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These data-gathering efforts will facilitate the collection of large num-
ber of samples and help the democratization of science by empow-
ering the citizen scientist. 
Metagenomics, Agriculture, and Food Microbiology 
For living entities, proper nutrition is a key factor for survival. Agri-
culture and food microbiology can benefit from metagenomics 
advanc es by improving food safety and security, improving the de-
tection of threats to food production and supply, and increasing the 
productivity of domestic animals and plants. In meat production, the 
ongoing use of direct-fed microbial could also be optimized in func-
tion of the food intake and the animal of choice.
The World Health Organization estimates that worldwide, approxi-
mately 2.2 million annual deaths are associated with foodborne and 
waterborne pathogens, including bacteria, viruses, and parasites.43 
Food and water safety is a worldwide necessity. The depth and high 
coverage of NGS makes metagenomics a powerful tool in the detec-
tion and surveillance of foodborne pathogens, the detection of out-
breaks and transmission routes of foodborne diseases, the testing of 
foods and food-associated environments, and the identification of mi-
crobiota that may protect against foodborne illnesses. 
Although the use of metagenomics approaches to test foods for 
the presence of specific foodborne pathogens can be problematic, 
its appli cation successfully identified the presence of serovars of Sal-
monella in samples that tested negative by bacteriological analytical 
manual meth ods and real-time polymerase chain reaction.43,44 In or-
der to facilitate the use of metagenomics by governmental agencies 
and the food industry, it is crucial to develop bioinformatics tools tai-
lored to the needs of the food microbiology laboratory and to put in 
place the appropriate legal and ethical framework for the collection 
and use of the data generated. The use of metagenomics approaches 
in the food industry, to better understand, the food-associated mi-
crobial communities, can lead to improvements in productivity, qual-
ity, and safety of food.43,45 
Eliminating hunger worldwide, providing desirable food to a larger 
population, and producing the needed food in a sustainable way are 
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major challenges facing future food security.46,47 A possible strategy 
for meeting those challenges in a sustainable way is to increase agri-
cultural yields and production limits by manipulating above–below-
ground plant interactions with the goal of reducing pests and increas-
ing crop growth. The association between plants and belowground 
soil-borne microbiota increases plant fitness. Plant growth promot-
ing rhizobacteria (PGPR) are able to influence plant growth and in-
crease plant resistance to her bivores and pathogens.47–49 Metage-
nomics approaches to uncover the in teractions between plants and 
belowground microbiota in agricultural systems are essential to tai-
lor and target these interactions for maximum benefit to the crops. 
More in-depth research in the composition and function of the rhizo-
sphere microbiome is needed in order to better un derstand and iden-
tify the activity of PGPR bacteria in different crops. The knowledge 
obtained by the analyses of rhizosphere microbiome can be used to 
design PGPR-based interventions that promote plant growth, nutri-
tion, and defense against pests in agricultural systems. The inocula-
tion of soils with beneficial bacteria such as PGPR could be a sustain-
able approach to increase productions of crops without the input of 
chemical fertilizers. Also, soil microbiota manipulation can be poten-
tially used to increase nitrogen fixation and reduce the use of fertiliz-
ers and subsequent nitrogenization resulting in economical and eco-
logical benefits.50,51 
Summary 
In this overview, we have highlighted some of the promises and pros-
pects of the utilization of omics approaches to the study of micro-
biomes. Clearly, there is still much work ahead before achieving a 
comprehensive understanding of the complex dynamics and interac-
tions within the hu man microbiome and other microbial ecosystems. 
At this time, microbi ome research is moving beyond the identifica-
tion of genes and/or taxa and toward an emphasis on the applica-
tion of multi-meta-omics tech nologies with the goal of sorting out the 
functions and pathways respon sible for the multidirectional interac-
tions between the microbiota, the host, and the environment. A com-
prehensive understanding of these in teractions will contribute to the 
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design of more effective, preventive, and therapeutic interventions. 
It creates opportunities for a new vision of health and disease treat-
ment that was not imagined in the 20th century. 
Many of the resources and technologies required to fulfil the prom-
ise of the microbiome are already available. The development of novel 
bioinformatics frameworks and analytical techniques are essential in 
order to more efficiently mine and synthesize the information of the 
so-called “Big Data” embedded in the present research or soon to be 
generated. 
It is interesting to note the concept of scale involved. From the in-
teraction at the atomic scale of the enzyme and its substrate, driv-
ing, in part, the functional assembly of a microbiome, to the dynamic 
interactions of biomes, we have moved from the nanometer to the 
meter range and beyond. Let’s be ready to stretch our minds a lit-
tle further and create the tools to better handle the rising concepts. 
This methodological and conceptual revolution has provided the 
magnification lens needed to better understand the unseen world in 
front of our eyes, the microbial communities inhabiting this planet for 
over 3.5 billion years. It is a scientific revolution that will soon reach 
every citizen. 
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